Zuccali G, Gherson G, Parenti M
Minerva Med. 1981 Feb 28;72(7):451-8.
The new preparation Broncaspin (guacetisal) has been experimented in the form of 1.2 g suppositories and 5% suspension, in 40 patients suffering from chronic bronchopneumopathy at acute phase. The drug exerted a marked therapeutic action in objective and subjective symptomatology in 87.5% of cases. The action was manifold in relation to the typical expectorant fluidifying, bronchiole disobstructing and anti-inflammatory characteristics of the drug. Tolerance was always excellent.
新型制剂溴卡司平（瓜西他柳）已制成1.2克栓剂和5%混悬液的剂型，在40例处于急性期的慢性支气管肺炎患者中进行了试验。该药物在87.5%的病例中对客观和主观症状均发挥了显著的治疗作用。其作用与该药物典型的祛痰、使痰液液化、解除细支气管阻塞及抗炎特性相关，具有多方面的作用。耐受性一直良好。
